DK0972201T3 - Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf - Google Patents

Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf

Info

Publication number
DK0972201T3
DK0972201T3 DK98911411T DK98911411T DK0972201T3 DK 0972201 T3 DK0972201 T3 DK 0972201T3 DK 98911411 T DK98911411 T DK 98911411T DK 98911411 T DK98911411 T DK 98911411T DK 0972201 T3 DK0972201 T3 DK 0972201T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
prostate cancer
immune diagnosis
immune
Prior art date
Application number
DK98911411T
Other languages
Danish (da)
English (en)
Inventor
Jiangchun Xu
Davin C Dillon
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DK0972201T3 publication Critical patent/DK0972201T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98911411T 1997-02-25 1998-02-25 Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf DK0972201T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659697A 1997-02-25 1997-02-25
US90480997A 1997-08-01 1997-08-01
US2074798A 1998-02-09 1998-02-09

Publications (1)

Publication Number Publication Date
DK0972201T3 true DK0972201T3 (da) 2006-01-02

Family

ID=27361502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911411T DK0972201T3 (da) 1997-02-25 1998-02-25 Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf

Country Status (13)

Country Link
US (1) US6887660B2 (enExample)
EP (2) EP0972201B1 (enExample)
JP (4) JP3844366B2 (enExample)
AR (1) AR012035A1 (enExample)
AT (1) ATE302414T1 (enExample)
BR (1) BR9807734A (enExample)
CA (1) CA2281954A1 (enExample)
CO (1) CO4870792A1 (enExample)
DE (1) DE69831222T2 (enExample)
DK (1) DK0972201T3 (enExample)
ES (1) ES2248891T3 (enExample)
IL (1) IL131539A0 (enExample)
WO (1) WO1998037418A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7270980B2 (en) * 1997-02-25 2007-09-18 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
IL131560A0 (en) 1997-02-25 2001-01-28 Corixa Corp Compounds for immunotherapy of prostate cancer and methods for their use
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2629442T3 (es) 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
DK1082341T3 (da) * 1998-06-01 2011-03-28 Agensys Inc Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
TW200728465A (en) * 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
IL142310A0 (en) * 1998-10-02 2002-03-10 Urogenesys Inc Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
EP1724351A3 (en) * 1999-03-11 2007-11-14 Mount Sinai Hospital Human Kallikrein-like genes
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
CO5450246A1 (es) * 1999-07-13 2004-10-29 Smithkline Beecham Corp Vacuna
US20030232056A1 (en) 1999-09-10 2003-12-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU7129700A (en) * 1999-09-10 2001-04-10 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6613515B1 (en) 1999-09-10 2003-09-02 Corixa Corporation Ovarian tumor sequences and methods of use therefor
US6720146B2 (en) 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6617109B1 (en) 1999-09-10 2003-09-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
GB9922835D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Novel compounds
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025446A1 (en) * 1999-10-07 2001-04-12 Schering Aktiengesellschaft Dna encoding prost 07 polypeptide
CA2391369A1 (en) * 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
RU2002121771A (ru) * 2000-01-14 2004-03-10 Корикса Корпорейшн (Us) Композиции и способы для терапии и диагностики рака предстательной железы
US7611892B2 (en) * 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2004504808A (ja) * 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
RU2276672C2 (ru) * 2000-04-10 2006-05-20 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук Антитело к фактору hldf, способ его получения (варианты), пептид с антигенными и нк-гидролизующими свойствами и способ диагностики анапластического состояния клетки человека
WO2001077682A1 (fr) * 2000-04-10 2001-10-18 Institut Bioorganicheskoi Khimii Imeni Akademikov M.M. Shemyakina I Ju. A. Ovchinnikova Rossiisskoi Akademii Nauk Anticorps diriges contre le facteur hldf, procedes de fabrication correspondants, peptides avec des capacites antigeniques et a hydrolyse hk et procede de diagnostic de l'etat anaplasique de cellules humaines
ATE534401T1 (de) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
AU2002236503C1 (en) 2000-11-28 2008-11-13 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2002241524A1 (en) 2000-11-28 2002-06-11 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1792912A3 (en) * 2002-04-02 2007-08-29 Curagen Corporation Novel proteins and nucleic acids encoding same
US20060234227A1 (en) * 2002-05-14 2006-10-19 Alexei Slesarev Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
US20080153104A1 (en) 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
US7276408B2 (en) * 2003-10-08 2007-10-02 Texas Instruments Incorporated Reduction of dopant loss in a gate structure
US7335744B2 (en) * 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
LT2486938T (lt) 2006-09-26 2018-06-25 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
JP5830015B2 (ja) 2009-06-05 2015-12-09 インフェクシャス ディズィーズ リサーチ インスティチュート 合成グルコピラノシル脂質アジュバント
US20120263754A1 (en) 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
CN103596586A (zh) 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
HUE039215T2 (hu) 2012-05-16 2018-12-28 Immune Design Corp Vakcinák HSV-2-höz
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
AU2015289773A1 (en) 2014-07-15 2017-02-02 Immune Design Corp. Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
WO2017180420A1 (en) 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
JP7195147B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｐｅｇ化リポソームおよび使用方法
JP7195148B2 (ja) 2016-05-16 2022-12-23 アクセス ツー アドバンスト ヘルス インスティチュート Ｔｌｒアゴニストを含有する製剤及び使用方法
KR102472026B1 (ko) 2016-06-01 2022-11-30 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
KR102755593B1 (ko) 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
EP4048308A1 (en) 2020-12-23 2022-08-31 Infectious Disease Research Institute Solanesol vaccine adjuvants and methods of preparing same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
AU3467493A (en) 1992-01-27 1993-09-01 Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives and methods for their use
WO1993014775A1 (en) * 1992-01-31 1993-08-05 Wright George L Jr Monoclonal antibody pd41 and antigen associated with prostate adenocarcinomas
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
JP4204642B2 (ja) * 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 前立腺に特異的な膜抗原
AU686660B2 (en) 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
AU699748B2 (en) 1994-05-10 1998-12-10 Hybritech Incorporated Recombinant HK2 polypeptide
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate

Also Published As

Publication number Publication date
ATE302414T1 (de) 2005-09-15
US20020081580A1 (en) 2002-06-27
WO1998037418A2 (en) 1998-08-27
US6887660B2 (en) 2005-05-03
AR012035A1 (es) 2000-09-27
JP3844366B2 (ja) 2006-11-08
EP1630235A3 (en) 2009-05-27
DE69831222T2 (de) 2006-07-13
CA2281954A1 (en) 1998-08-27
JP2008249727A (ja) 2008-10-16
WO1998037418A3 (en) 1999-02-25
JP2001513886A (ja) 2001-09-04
CO4870792A1 (es) 1999-12-27
IL131539A0 (en) 2001-01-28
EP0972201A2 (en) 2000-01-19
JP2006201187A (ja) 2006-08-03
EP0972201B1 (en) 2005-08-17
EP1630235A2 (en) 2006-03-01
ES2248891T3 (es) 2006-03-16
BR9807734A (pt) 2000-10-31
DE69831222D1 (de) 2005-09-22
JP2007114212A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
DK0972201T3 (da) Forbindelser til immundiagnosticering af prostatacancer og fremgangsmåder til anvendelse heraf
NO994069D0 (no) Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
NO984229D0 (no) Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
IS2468B (is) Aðferðir og milliefni til framleiðslu á efnasamböndum gegn krabbameini
DK0781136T3 (da) Forbindelser og fremgangsmåder til behandling af cancer
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
NO20010196L (no) Sammensetninger og fremgangsmÕter for terapi og diagnose av prostatakreft
NO996253D0 (no) Diagnostiske midler og legemidler for maligne tumorer
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
DK0752870T3 (da) Anvendelse af Mycobacterium til behandling af tumorer
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
ID21818A (id) Metode verifikasi lokasi deret detektor
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
NZ501742A (en) Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
DE69812879D1 (de) Patientenliege
DK1157041T3 (da) Antistoffer til diagnose og behandling af cancer
ZA981585B (en) Compounds for immunotherapy of prostate cancer and methods for their use
ZA981536B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
SE9401687D0 (sv) Method of detecting cancer
SE9401527D0 (sv) Method of detecting cancer
DK9700076U3 (da) Måleapparatur til behandling af rygpatienter
ID21264A (id) Peningkatan pci berdaya-guna tinggi